ARTICLE | Clinical News
iCo-007: Phase I start
January 29, 2007 8:00 AM UTC
This half, iCo will begin a dose-escalation Phase I trial. In 2005, ISIS granted iCo exclusive rights to the compound to treat eye diseases caused by choroidal neovascularization (see BioCentury, Aug....